Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of ALXN2050 with Cyclosporine, Tacrolimus, and MMF in Healthy Volunteers
NCT05202145Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vemircopan in lupus nephritis (LN) and IgA nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Concentration-Time Curve From Time Zero To The 12-hour Time Point (AUC0-12) Following Multiple Dose Cyclosporine, ALXN2050 AUC0-12 Following Multiple Dose ALXN2050 and 12 more. Started Jan 2022; status: completed.
02
Drugs
vemircopan
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05202145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202145.